Journal article
Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials
Abstract
BackgroundAnthracyclines can cause dose-dependent cardiotoxicity that may be irreversible. To minimize cardiotoxic effects, substituting doxorubicin for liposomal doxorubicin (LD) has been explored as a cardioprotective strategy.ObjectivesTo describe randomized clinical trials (RCTs) comparing the efficacy and safety of LD with other anthracycline-based regimens.MethodsWe conducted a systematic review and meta-analysis of RCTs comparing LD with …
Authors
Cavalli GD; Lopez-Lopez JP; Carandang FC; Johnstone A; Scampoli S; Rana R; Meireles PT; Petropoulos J-A; Hillis C; Balitsky A
Journal
Cardio-Oncology, Vol. 11, No. 1,
Publisher
Springer Nature
DOI
10.1186/s40959-025-00375-w
ISSN
2057-3804